Familywise error control in multi-armed response-adaptive trials.
David S RobertsonJames M S WasonPublished in: Biometrics (2019)
Response-adaptive designs allow the randomization probabilities to change during the course of a trial based on cumulated response data so that a greater proportion of patients can be allocated to the better performing treatments. A major concern over the use of response-adaptive designs in practice, particularly from a regulatory viewpoint, is controlling the type I error rate. In particular, we show that the naïve z-test can have an inflated type I error rate even after applying a Bonferroni correction. Simulation studies have often been used to demonstrate error control but do not provide a guarantee. In this article, we present adaptive testing procedures for normally distributed outcomes that ensure strong familywise error control by iteratively applying the conditional invariance principle. Our approach can be used for fully sequential and block randomized trials and for a large class of adaptive randomization rules found in the literature. We show there is a high price to pay in terms of power to guarantee familywise error control for randomization schemes with extreme allocation probabilities. However, for proposed Bayesian adaptive randomization schemes in the literature, our adaptive tests maintain or increase the power of the trial compared to the z-test. We illustrate our method using a three-armed trial in primary hypercholesterolemia.
Keyphrases
- study protocol
- systematic review
- end stage renal disease
- phase iii
- healthcare
- chronic kidney disease
- primary care
- cardiovascular disease
- newly diagnosed
- skeletal muscle
- prognostic factors
- electronic health record
- big data
- metabolic syndrome
- machine learning
- patient reported outcomes
- open label
- glycemic control
- patient reported